Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This study is testing a new cell therapy called BG1805 for people with acute myeloid leukemia (AML) — a cancer of the blood — that has come back or stopped responding to treatment. Researchers want to find out if this treatment is safe and effective. **You may be eligible if...** - You are 18–70 years old - You have been diagnosed with relapsed or refractory AML that has returned after remission or did not respond to at least 2 standard treatments - Your leukemia cells test positive for a specific protein called CLL-1 (≥50%) - You are in generally good health (able to carry out normal activity) and expected to live more than 3 months - Your liver, kidneys, and heart are functioning adequately **You may NOT be eligible if...** - You have a type of AML called acute promyelocytic leukemia - You have another active cancer diagnosed in the last 3 years - You have cancer that has spread to the brain or spinal fluid - You have active hepatitis B, hepatitis C, HIV, or syphilis - You have had a stem cell transplant within the last 6 months - You have received CAR-T or other cell therapy before - You have severe heart disease or uncontrolled infection Talk to your doctor to see if this trial is right for you.